* India anti-diabetic/weight loss opportunity: With India leading the world in diabetes (212 Mn cases as of 2022, per WHO) and obesity (70 Mn cases, per The Lancet), demand for GLP-1 drugs is set to surge
Moreover, combining these bioactives with standard therapies such as metformin or letrozole has the potential to enhance outcomes while reducing required drug doses, thereby minimizing adverse effects
Some people experience hair loss while on these medications but its not usually the medication itself that is to blame
Indications Do not exceed daily-recommended dose
These effects can be reversed by ferroptosis inhibitors DFO and Fer-1, 110 indicating that the combination of cetuximab and -elemene inhibits EMT by promoting ferroptosis
Patients using Semaglutide often report feeling more energetic and capable of engaging in physical activity, further amplifying the health benefits